TABLE 3

National Estimates of Medication-Related AEs Among Children <12 Years of Age Treated in EDs Before and After Voluntary Withdrawal of OTC Infant CCMs: United States, July 22, 2006 to December 31, 2008

Patient AgeED Visits Before Voluntary WithdrawalED Visits After Voluntary WithdrawalDifference in Proportions (95% CI), %
No. of CCM-Related VisitsNo. of All Medication-Related VisitsProportion of CCM-Related Visits Among All Medication-Related Visits, %No. of CCM-Related VisitsNo. of All Medication-Related VisitsProportion of CCM-Related Visits Among All Medication-Related Visits, %
<2 y279072 7173.8124871 9341.7a−2.1 (−3.8 to −0.4)
2–11 y6937105 5706.68160106 3447.71.1 (−1.4 to 3.6)
Total9727178 2875.59408178 2785.3−0.2 (−2.0 to 1.6)
  • Estimates were from the 2006–2008 NEISS-CADES project, Centers for Disease Control and Prevention. CCMs refer to orally administered prescription or OTC drug products that contain decongestant, antihistamine, antitussive, and/or expectorant combinations, as well as single-ingredient decongestants and antitussive agents/expectorants. All medications refer to prescription or OTC medications including vitamins, herbal preparations/dietary supplements, and vaccines. Voluntary market withdrawal of OTC CCMs labeled for infants was announced on October 11, 2007. The period before withdrawal refers to the 14-month period beginning July 22, 2006, and ending October 11, 2007; the period after withdrawal refers to the 14-month period beginning October 12, 2007, and ending December 31, 2008.

  • a Estimate with coefficient of variation of 30.6.